Thalidomide, Bortezomib and Lenalidomide - Three Drugs that Changed Multiple Myeloma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33151199" target="_blank" >RIV/61989592:15110/14:33151199 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Thalidomide, Bortezomib and Lenalidomide - Three Drugs that Changed Multiple Myeloma

Popis výsledku v původním jazyce

Multiple myeloma (MM) is a hematological malignancy with a very heterogenous presentation, course and prognosis. Despite an immense progress in the understanding of the tumour biology, neoplastic transformation and progression, we still do not know all the processes that contribute to the multistep pathogenesis of this disease. {/p}{p} For quite a long time there have been a lot of efforts at the improvement of therapeutic approaches in order to intensify the treatment to reach a better response rate, and to prolong the overall survival in MM patients. For more than 30 years, combined chemotherapeutic regimens, and later on high-dosed regimens with autologous stem cell transplantation tried to establish the best approach, however, none of the conventional regimens finally turned out to be significantly superior than the regimen MP (melphallan and prednisone) in the elderly, and HD-ASCT (high-dosed chemotherapy with support of autologous stem cell transplantation) in younger patients. {

Název v anglickém jazyce

Thalidomide, Bortezomib and Lenalidomide - Three Drugs that Changed Multiple Myeloma

Popis výsledku anglicky

Multiple myeloma (MM) is a hematological malignancy with a very heterogenous presentation, course and prognosis. Despite an immense progress in the understanding of the tumour biology, neoplastic transformation and progression, we still do not know all the processes that contribute to the multistep pathogenesis of this disease. {/p}{p} For quite a long time there have been a lot of efforts at the improvement of therapeutic approaches in order to intensify the treatment to reach a better response rate, and to prolong the overall survival in MM patients. For more than 30 years, combined chemotherapeutic regimens, and later on high-dosed regimens with autologous stem cell transplantation tried to establish the best approach, however, none of the conventional regimens finally turned out to be significantly superior than the regimen MP (melphallan and prednisone) in the elderly, and HD-ASCT (high-dosed chemotherapy with support of autologous stem cell transplantation) in younger patients. {

Druh

C - Kapitola v odborné knize

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Frontiers in Clinical Drug Research-Hematology

ISBN

978-1-60805-859-4

Počet stran výsledku

76

Strana od-do

103-178

Počet stran knihy

378

Název nakladatele

Bentham Science

Místo vydání

UK

Kód UT WoS kapitoly

—